---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-068591"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2026-06-01T12:00:26+00:00"
generated_at: "2026-06-01T12:07:02.711114+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's

## Summary
- VY1706 targets intra- and extracellular tau; IND cleared by FDA on June 1, 2026.
- Phase 1 open-label, dose-escalation trial expected to begin dosing in H2 2026.
- Trial to enroll up to 18 early AD patients across 3 cohorts; highest dose 5 x 10^13 vg/kg.
- Primary endpoint: safety/tolerability; secondary endpoints: CSF tau biomarkers and tau PET imaging.
- Company plans to initiate multi-site study; VY1706 administered as one-time IV dose.

## SEC filing metadata
- accession: 0001104659-26-068591
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2026-06-01T12:00:26+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465926068591/0001104659-26-068591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465926068591/tm2616041d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-068591
- JSON: https://secwatch.observer/filing/0001104659-26-068591.json
- Plain text: https://secwatch.observer/filing/0001104659-26-068591.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.